Physician profile
Michael E Machen
NPI 1336186196
$1,657.03
in general payments reported to CMS, 2019-2025
20 companies · $196 in 2025
The $196 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $79.16 · 2020: $71.22 · 2021: $463 · 2022: $286 · 2023: $148 · 2024: $414 · 2025: $196.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $758.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $758.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $309.12 | 2021-2025 | Mounjaro, Zepbound |
| Amgen INC. | $292.24 | 2019-2025 | Evenity, Prolia, Repatha |
| Abbvie INC. | $255.83 | 2021-2025 | |
| Pfizer INC. | $126.47 | 2019-2024 | |
| Novo Nordisk INC | $104.90 | 2021-2025 | Rybelsus, Ozempic |
| Novartis Pharmaceuticals Corporation | $78.40 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $74.79 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $66.56 | 2020-2024 | Trintellix |
| Dexcom, INC. | $59.14 | 2021-2025 | Dexcom Stelo Glucose Biosensor, Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Biogen, INC. | $55.97 | 2023-2024 | Skyclarys, Skyclarys |
| Bioventus LLC | $41.86 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $32.78 | 2025 | Evkeeza |
| Sumitomo Pharma America, INC. | $28.72 | 2024 | Gemtesa |
| Sunovion Pharmaceuticals INC. | $27.48 | 2019-2021 | |
| Abbott Laboratories | $22.28 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $22.08 | 2025 | The Cologuard Plus Collection Kit |
| Biohaven Pharmaceutical Holding Company Ltd. | $16.65 | 2022 | |
| Melinta Therapeutics, LLC | $15.23 | 2021 | |
| Glaxosmithkline, LLC. | $14.32 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $12.21 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Machen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.